Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
The European Community Advisory Board

ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies, a major limitation that ECAB successfully overcame by putting forward an innovative model for the patient Community to provide meaningful, independent, and valued input in HIV treatment and prevention research.


EATG, within the remit of the European Community Advisory Board (ECAB), addresses critical scientific questions around HIV drug-development and related co-infections as well as access to treatment in the European region as defined by the World Health Organisation.


ECAB is a high-level scientific platform that brings together civil society, scientific researchers, the pharmaceutical industry and international institutions to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis.


ECAB is composed by expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena.  It is a volunteer, Community-based structure, also collaborating actively with national and regional Community Advisory Boards in Europe and other groups sharing the same philosophy in other
geographical areas. The majority of ECAB members are living with HIV. ECAB members represent the diverse needs, interests, and concerns of the entire spectrum of the European HIV patient community (women, men, IDUs, ethnic minorities, people in detention, vulnerable groups etc.).


ECAB aims to promote the harmonisation of the best available clinical practices, standards of care and access to the latest and best available therapies and diagnostic tools throughout Europe, with a particular regard to Central and Eastern Europe. ECAB members meet regularly with the pharmaceutical industry and researchers to discuss, under confidentiality, the advances in HIV drug development and related co-infections, and access to treatment in the European region.

ECAB ‘s work includes:

  • Reviewing clinical trial protocols giving the point of view of PLHIV Community
  • Promoting best practices procedures and ethics
  • Promoting universal access to fair, sustainable, affordable drugs
  • Promoting research developments improving the quality of living for PLWHA

Members of the ECAB meet in Brussels on a regular basis (see ECAB calendar of meetings)


ECAB meetings don't only focus on HIV/AIDS. Thematic ECAB meetings are also organised on important topics such as hepatitis C or tuberculosis as co-infections. The coinfection ECAB meetings discuss clinical development, and expanded use of treatments for people living with HIV who are also infected with extensively drug-resistant and multi drug resistent forms of tuberculosis or hepatistis C.

During the first semester of 2014 two HIV ECAB meetings  were held in Brussels (February and April) and on on hepatitis C in June in Lisbon. Another HIV ECAB will take place in Brussels in October and a second hepatitis C ECAB will take place in London in December.


ECAB Steering Committee

Chair : Giulio Maria Corbelli

Scientific  Officer : Giorgio Barbareschi

Steering Committee Members :

Paul Clift

Fatih Egeliogu

Sanja Kovacevic

Memory Sachikonye

Alain Volny Anne


Luis Mendao (BoD Liaison)

Andrej Senih (Policy Working Group Liaison)

Tags: ECAB

The ECAB Chair

Giulio Maria Corbelli is the Current ECAB Chair. He has been confirmed during the EATG General Assembly of 2014

Tags: ECAB

How ECAB works

ECAB holds meetings at least 4 times per year for 3 days each. The meeting agenda includes discussions with industry and scientists, lectures by researchers and training sessions.


ECAB members commit to work as group members and on specific tasks they might be assigned to (i. e. company liaison, thematic portfolios, minute taking etc.).


ECAB asks pharmaceutical companies to disclose information of scientific and commercial value as it is available and prior to publication. ECAB receives such information under confidentiality.

Other information shared by companies during ECAB meetings (i. e. expanded access programmes, published studies) is not subject to confidentiality.

ECAB objectives and priorities include:

  • Promoting best practices procedures and ethics;
  • Promoting universal access to fair, sustainable and affordable drugs;
  • Promoting research developments improving the quality of live of PLWHA;
  • Reviewing clinical trial protocols at planning stage, giving the point of view of the PLWHA Community;
  • Monitoring ongoing trials: adverse events, compliance, community priorities;
  • Staying informed of interim results;
  • Representing PLWHA interests, in particular clinical trial participants;
  • Reviewing informed consent forms (content, language);
  • Promoting best practice procedures and ethics;
  • Representing patients’ perspective within investigator / advisory meetings, DSMBs;
  • Promoting universal access to fair, sustainable, affordable treatment, diagnostics and prevention tools in WHO Europe countries;
  • Supporting efforts to harmonise safety reporting in Europe, and better involvement of patients in AE reporting;
  • Promoting research on New Prevention Technologies (NPT) and Immune Based Therapies (IBT);
  • Promoting development of improved & effective therapies for hepatitis, tuberculosis and co-infected patients;
  • Addressing the specific needs of vulnerable populations;
  • Working proactively, anticipating treatment needs of HIV-positive people;
  • Benchmarking EATG influence on clinical research and drug development, review and identify the most needed changes and effective methods, and develop a strategy for scaling up of proven interventions.

Tags: ECAB